

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 May 2023 (11.05.2023)



(10) International Publication Number
WO 2023/081781 A1

(51) International Patent Classification:

C12N 15/86 (2006.01) A61K 48/00 (2006.01)
A61K 38/47 (2006.01) A61P 3/00 (2006.01)

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/079249

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

03 November 2022 (03.11.2022)

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/275,390 03 November 2021 (03.11.2021) US
63/373,826 29 August 2022 (29.08.2022) US

(71) Applicant: SANGAMO THERAPEUTICS, INC.
[US/US]; 7000 Marina Blvd., Brisbane, CA 94005 (US).

(72) Inventors: PASSALACQUA, Cristobal; c/o Sangamo
Therapeutics, Inc., 7000 Marina Blvd., Brisbane, CA 94005
(US). HUSTON, Marshall; c/o Sangamo Therapeutics,
Inc., 7000 Marina Blvd., Brisbane, CA 94005 (US). SOU-
BERBIELE, Bernard; c/o Sangamo Therapeutics, Inc.,
7000 Marina Blvd., Brisbane, CA 94005 (US).

(74) Agent: KIM, Ji Eun et al.; Sterne, Kessler, Goldstein &
Fox P.L.L.C., 1100 New York Avenue, NW, Washington,
DC 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE

(57) Abstract: The present disclosure relates to the methods for treating or ameliorating one or more symptoms of Fabry disease, reducing the amount of glycosphingolipids, and/or increasing an α galactosidase A (α -Gal A) protein activity in a subject in need thereof by administering the expression vectors (e.g., an AAV expression vector) comprising an α galactosidase A (α -Gal A) expression cassette, which comprises an α galactosidase A (α -Gal A) transgene encoding the at least one α -Gal A protein at a dose of about 5×10^{12} vector genomes per kilogram of body weight (vg/kg) to about 5×10^{13} vg/kg.

WO 2023/081781 A1